TGTX - TG Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.396B

Cash

209.8M

Avg Qtr Burn

N/A

Short % of Float

28.40%

Insider Ownership

9.55%

Institutional Own.

59.50%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BRIUMVI (Ublituximab) (CD20) Details Multiple sclerosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TG-1801 (anti-CD47/anti-CD19) Details B-cell malignancies, Cancer, B-cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TG-1701 (BTK inhibitor) Details Chronic lymphocytic leukemia, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UKONIQ® (Umbralisib) (PI3K-delta & CK1-epsilon inhibitor) Details FL (Follicular Lymphoma)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Umbralisib (PI3K-delta & CK1-epsilon inhibitor) + Ublituximab (CD20) Details R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.